Lexaria's DehydraTECH-CBD Enhances Performance Compared to Epidiolex in Seizure Study Program

Stock Information for Lexaria Bioscience Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lexaria Bioscience Corp.

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
Lexaria Awarded New Patents
Lexaria to Present at The LD Micro Invitational XIV
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.